Welcome to our dedicated page for AVITA Medical SEC filings (Ticker: RCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AVITA Medical's SEC filings document its therapeutic acute wound-care business, RECELL-related commercial activity, operating results, capital structure, and corporate governance. Form 8-K reports include quarterly and annual financial results, material definitive agreements, credit-facility amendments and refinancing activity, leadership appointments, and board-structure changes.
Proxy materials describe annual meeting matters such as director elections, auditor ratification, non-executive director compensation, equity-award approvals, and governance requirements tied to the company's U.S. listing and ASX-related matters. The filings also provide formal disclosure around debt obligations, subsidiary guarantees, shareholder voting items, executive compensation arrangements, and risk areas affecting AVITA Medical's wound-care operations.
AVITA Medical (RCEL) announced leadership changes. Effective October 16, 2025, James Corbett departed as Chief Executive Officer and director; the company stated his departure was not due to any disagreement regarding operations, policies, or practices. The Board appointed Chairman Cary Vance as Interim CEO, and named Jan Reed as Lead Independent Director.
Vance brings nearly 30 years of healthcare leadership experience, including CEO roles at PhotoniCare, Titan Medical, and others. As Interim CEO, he will receive an annual base salary of $702,000 and a guaranteed bonus of $140,000 for fiscal 2025. For fiscal 2026, he is eligible for a target bonus equal to 80% of base salary, with half guaranteed and half tied to performance metrics, subject to continued service through the one-year anniversary of the effective date. He will forgo Board compensation while serving as Interim CEO and will be reimbursed for commuting expenses per company policy.
Avita Medical director Robert McNamara reported a personal purchase of company stock on 08/28/2025. The Form 4 shows a purchase of 10,000 shares of Avita Medical common stock at $4.50 per share. After the transaction he beneficially owns 86,771 shares, a figure the filing notes includes unvested restricted stock units. The filing identifies McNamara as a director and was signed by an authorized power of attorney on 08/29/2025. The document lists no derivative transactions and provides no additional financial results or forward-looking statements.
Insider purchase reported: Avita Medical (RCEL) CFO David O'Toole purchased 2,000 shares of the company's common stock on 08/26/2025 at a price of $4.52 per share. After the transaction he beneficially owns 31,657 shares in a direct capacity. The filing shows no amendments and no derivative transactions were reported.
Avita Medical, Inc. (RCEL) director Robert McNamara reported a purchase of 10,000 shares of the company's common stock on 08/19/2025 at a price of $5.00 per share, bringing his beneficial ownership to 76,771 shares. The Form 4 was signed by power of attorney on 08/20/2025.
AVITA Medical, Inc. entered into a placement agreement to sell 17,201,886 CHESS Depositary Interests (CDIs) to Australian institutional and professional investors at approximately AU$1.32 per CDI. Five CDIs represent one share of common stock.
The Company expects aggregate proceeds of about US$15 million (A$22.7 million) and will pay placement agent fees valued at approximately US$0.8 million in cash and CDIs. The unregistered Placement relies on Regulation S for offerings made outside the United States and is expected to close on or about August 19, 2025.
David O'Toole, identified as the Chief Financial Officer, filed a Form 4 reporting a change in beneficial ownership of Avita Medical, Inc. (RCEL). The filing shows he acquired 2,000 shares of common stock on 08/12/2025 at a price of $4.81 per share, increasing his direct holdings to 29,657 shares. The transaction is reported under transaction code P and the Form 4 was filed by one reporting person.
AVITA Medical, Inc. filed a Current Report on Form 8-K dated August 12, 2025, reporting that the company issued a press release announcing the successful completion of an equity raise in Australia. The filing states the press release is attached as Exhibit 99.1 and clarifies that the information furnished, including the exhibit, is not "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated. The 8-K is signed by Chief Financial Officer David O'Toole. The company's common stock trades under the symbol RCEL on Nasdaq.
AVITA Medical, Inc. has filed a Form S-8 to register an additional 2,500,000 shares of common stock under its 2020 Omnibus Incentive Plan following stockholder approval on June 4, 2025. The filing also registers an aggregate of 605,902 shares that are issuable upon exercise or vesting of previously approved awards, comprised of 545,770 stock options and 60,132 restricted stock units.
The registration incorporates by reference prior S-8 filings and recent SEC reports, including the Annual Report for the year ended December 31, 2024 and quarterly reports for the quarters ended March 31, 2025 and June 30, 2025. The filing describes indemnification provisions under Delaware law, charter and bylaw exculpation language, indemnification agreements with directors and officers, and directors' and officers' liability insurance.
AVITA Medical (Nasdaq: RCEL; ASX: AVH) is issuing 400,000 new common shares to two OrbiMed-affiliated lenders in lieu of cash as consideration for a Fifth Amendment to its $40 million secured Credit Agreement. The shares will be delivered on or about 8 Aug 2025; no cash proceeds will be received.
The amendment reduces near-term revenue covenants that trigger mandatory principal amortisation, giving AVITA greater flexibility during FY-25/26 while it scales its FDA-approved RECELL wound-care platform. If future revenue again falls short, the company must repay 5 % of outstanding principal each quarter and pay related fees. Debt remains secured against substantially all assets and is exposed to rising rates.
Following the issue, total basic share count will rise modestly (≈1.5 % based on ~26 M shares outstanding), causing limited dilution. AVITA remains an Emerging Growth Company and does not expect to pay dividends. Key risks disclosed include covenant breach, liquidity pressure, equity volatility and macroeconomic factors.
AVITA Medical, Inc. (RCEL) filed an 8-K announcing a Fifth Amendment to its October 18 2023 Credit Agreement with OrbiMed affiliates. The amendment lowers trailing-12-month revenue covenants for the next four quarters to $73 m (Q3-25), $77 m (Q4-25), $90 m (Q1-26) and $103 m (Q2-26). The original $115 m covenant is reinstated from Q3-26 through the debt’s maturity.
In consideration, the Company will issue 400,000 registered common shares to the lenders, using its effective Form S-3 shelf. All other terms of the credit facility remain unchanged.
Item 2.02 notes release of Q2-25 financial results via Exhibit 99.1, but the filing itself does not include those figures.